New nanocrystal drug aims to fight cancer wasting during chemoradiation
NCT ID NCT07338487
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new, easier-to-absorb version of megestrol acetate (a drug that stimulates appetite) in 5 women with advanced cervical cancer who are undergoing chemoradiation. The goal is to see if it helps them maintain weight and improve nutrition during treatment. The study compares the drug plus standard therapy against standard therapy alone over 8 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Nanocrystalline megestrol acetate oral suspension
What this could lead to
If it works, this could help patients with advanced cervical cancer maintain weight and appetite during chemoradiation, potentially improving treatment tolerance and quality of life.
What could go wrong
This is a very early phase 1 trial with only 5 participants, so results may not apply to everyone. The drug may cause side effects or fail to show benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Xiangya Second Hospital of Central South University
RECRUITINGChangsha, Hunan, 410011, China
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••